Richard Satterwhite doesn’t have any trouble remembering dates. Among those that will stay with him: Sept. 6, Oct. 24 and Dec. 14. These are the dates that Richard associates with milestones in his experience with prostate cancer.
Most men who are diagnosed with prostate cancer face one of just a few options for their treatment plan: watchful waiting—having their physician monitor the level of their prostate-specific antigen, or PSA, to ensure it doesn’t rise incrementally—or curative therapy, usually surgery.
One of the most well-known—and controversial—methods of cancer detection is the PSA test. PSA stands for prostate-specific antigen, the marker in blood that can indicate the presence of prostate cancer.
As Immunotherapy Awareness Month winds down, we want to highlight three different clinical trials being led by physicians at our Center for Immunotherapy of novel immunotherapy approaches for treating genitourinary cancers.